Transcript of Earnings call

Phone

+91-1795-650820

May 26, 2025

To, To,

BSE Limited National Stock Exchange of India Limited

Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor

Dalal Street, Mumbai – 400001 Plot No. C/1, “G” Block

BSE Symbol

INNOVACAP Bandra-Kurla Complex

BSE Scrip Code

544067 Bandra (E), Mumbai – 400 051

NSE Symbol

INNOVACAP

Subject

Transcript of the Investor/Analyst Earnings Call held on Monday, May 20, 2025.

Dear Sir/Madam,

This is in continuation to our letter dated May 20, 2025, wherein we had informed regarding the audio link of the earnings call with analysts/investors for the quarter and year ended March 31,

2025.

In this regard, please find enclosed herewith the transcript of the said call.

The transcript is also available on the Company’s website i.e. https://innovacaptab.com

You are requested to take this information on record.

Thanking you,

Yours faithfully,

For Innova Captab Limited

Neeharika Shukla

Company Secretary & Compliance Officer

Membership No.

A42724

Encl.

A/a

Registered Office - 601, Proxima, Plot No 19, Sector 30 A Vashi, Navi Mumbai, Thane, Maharashtra, India, 400705

CIN - L24246MH2005PLC150371, email - [email protected]

“Innova Captab Limited

Q4 FY '25 Earnings Conference Call”

May 20, 2025

E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recordings uploaded on the stock exchange on 20th May 2025 will prevail.

MANAGEMENT

MR. VINAY LOHARIWALA – MANAGING DIRECTOR –

Moderator

Ladies and gentlemen, good day, and welcome to the Innova Captab Limited Q4 and FY '25

Earnings Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal your operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded.

Before we begin, a brief disclaimer. This conference call may contain forward-looking statements about the company, which are based on beliefs, opinions and expectations of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict.

I now hand the conference over to Mr. Ayush Kumar Garg, Head IR. Thank you, and over to you, sir.

Ayush Kumar Garg

Thank you, Saisha. Good morning, everyone, and thank you for joining us on the earnings call today to review the operational and financial performance for Q4 and FY '25. We have with us

Mr. Vinay Lohariwala, Managing Director; Mr. Lokesh Bhasin, Chief Financial Officer; and

SGA, our Investor Relations Advisor.

We trust that you have had a chance to review the financial results and investor presentation, which have been made available on the Stock Exchanges as well as on the company website.

With that, I'll now hand over the call to Mr. Vinay for his opening remarks. Thank you, and over to you, sir.

Vinay Lohariwala

Thank you, Ayush. Good morning and thank you all for joining us on today's earnings call. Let me begin by saying that, I'm pleased with the way Innova Captab has performed throughout the year. We closed FY'25 with total revenue of INR1,244 crores, delivering strong growth of 15%.

For Q4, revenue stood at INR315 crores, reflecting a robust year-on-year growth of 20%. A major milestone for us this quarter was the launch of commercial production at our new facility in Kathua, Jammu.

I would like to make a moment to extend my sincere gratitude to the entire execution team, whose dedication was instrumental in bringing the critical project to successful completion. The relentless efforts, coordination and commitment to excellence played a key role in ensuring that we met our goals on time and to the highest standard.

We have started offering new products and dosage form from this plant and the initial traction has been encouraging. This gives us added confidence in the long-term potential of this facility.

Let me now take you through the performance highlights across each of our business area.

CDMO business- Our CDMO business made significant strides this year. We expanded our client base to over 200 customers, which includes some of the largest players in the Indian pharmaceutical market. Our product portfolio has grown from 2,900-plus products last year to over 3,300 this year, a clear testimony to our commitment to quality, innovation and customer centricity.

Page 2 of 14

Innova Captab Limited

May 20, 2025

The business recorded a year-on-year growth of 12% in Q4 and 6% for the full year. Going forward, our strategy will centre on acquiring new clients while also increasing wallet share from our existing partners. New product and dosage form launches from the Kathua plant are expected to further accelerate our growth in this area.

Domestic Branded Generic - Our domestic branded generic business delivered a stellar performance with year-on-year growth of 30% in Q4 and 21% in full year. We continue to expand our distribution network, which now includes over 6,000 distributors, up from 5,000 last year. We also significantly enhanced our market reach now touching more than 220,000 pharmacy and stockists compared to 150,000 in FY '24.

Our product offering in this business increased to over 750, up from 600 plus last year. Our focus in this area remains on supporting existing distributor retailer, while engaging new partners and channels to boost market presence.

International Business - On the international front, Innova now has a presence in 30-plus countries, including regulated markets such as the U.K. and Canada. This presence was 25-plus countries last year. The business posted solid year-on-year growth of 47% in Q4 and 25% for the full year.

Looking ahead, we will continue to expand our footprint in both regulated and semi-regulated market while also broadening our product offering to cater to diverse international demands.

Sharon Bio-Medicine - Sharon closed this year with revenue of INR197 crores. Sharon has a robust presence in regulated market and supplies both formulation and API to some of the most well-known pharmaceutical companies globally. We aligned strategic initiatives and leveraging synergy with Innova Captab.

Sharon is well positioned for sustained growth and enhanced value creation in the year ahead.

Our strategic initiatives have started taking shape, and we are well positioned to enter the next phase of our growth journey.

The newly commissioned Kathua plant is set to unlock a broad spectrum of opportunity, expanding our product portfolio across business area, fostering new partnerships and deepening engagement with existing clients through enhanced wallet share. We are already witnessing strong interest from our current and prospective partner refirming the potential of this facility.

Our commitment to innovation is equally reflected in our R&D infrastructure.

Our dedicated laboratory and pilot scale manufacturing centre in Baddi, Himachal Pradesh is recognized by DSIR, Department of Science and Industrial Research. Further, our upcoming facility in Panchkula, Chandigarh will strengthen our capability with a focus on the development of complex generic and differentiated formulation, an important step in enhancing our innovation pipeline.

With multiple growth levers in place, including capacity expansion, a broadening product base, deepening market penetration and a robust R&D engine, we are confident in our ability to deliver long-term value to our all stakeholders. We are proud to the progress we have made and remain

Page 3 of 14

Innova Captab Limited

May 20, 2025 committed to executing our strategic road map with discipline and agility to drive sustainable growth across all verticals.

Thank you once again for your continued support and trust in Innova Captab. I now hand over the call to Mr. Lokesh to take you through the financial performance in more detail.

Lokesh Bhasin

Thank you, sir, and good morning, everyone. I will now take you through the financial highlights for Quarter 4 and full year FY '25.

Quarter 4 FY '25

Our consolidated revenue stood at INR314.7 crores, registering year-on-year growth of almost

20%. CDMO clocked INR154.8 crores of revenue with year-on-year growth of 12%, supported by sustained traction in existing products and the contribution that we got from our new Kathua,

Jammu facility.

Domestic Branded Generic business delivered a robust growth of 30% to INR61.7 crores fuelled by expanded product portfolio and increased market penetration. International Branded Generic business delivered year-on-year growth of 47% to INR43.4 crores, driven by product and market expansion.

Sharon recorded a revenue of INR54.9 crores with year-on-year growth of 15%. This was chiefly volume driven. We witnessed decent growth in our absolute EBITDA, which was INR51.1 crores vis-a-vis INR43.8 crores of previous year -- previous quarter, Quarter 4 FY '24, recording a growth of 17%. This was largely driven by improved gross conversion. The EBITDA margin for the quarter was 16.2%.

The PAT rose by 3% year-on-year to INR29.6 crores of Quarter 4 '25 PAT after absorbing the impact of depreciation and finance cost accruing from the Kathua, Jammu plant, which was commercialized in January 2025. Consequently, PAT margin stood at 9.4%.

On a full year FY '25 basis.

The total revenue from operations grew 15% at INR1,243.7 crores, led by volume growth across business areas. The business mix for the year was CDMO 53%, Domestic Generic business was

18%, International Branded Generics was 13%, and Sharon contributed 16%. In absolute terms, business area-wise revenues for the financial year were CDMO, INR659.9 crores; Domestic

Generic business, INR230.7 crores; International Generic business, INR156.3 crores; and

Sharon, INR196.8 crores.

Coming to profitability. EBITDA registered stellar year-on-year growth of 19% to INR198.2 crores, almost touching INR200 crores, owing to improved gross contribution. EBITDA margin also increased by 50 basis points to 15.9%. The PAT witnessed robust growth of 36% to

INR128.3 crores, mainly driven by higher EBITDA, coupled with reduced finance costs. PAT margins improved by 160 basis points to 10.3%.

Page 4 of 14

Innova Captab Limited

May 20, 2025

Our balance sheet has also shown continued resilience with the strategic decision taken over the last few years now being in execution. We believe our performance metrics will further improve in coming years.

With this, we would like to conclude the presentation and open the floor for question and answers. Thank you very much.

Moderator

The first question is from the line of Amey Chalke from JM Financial.

Amey Chalke

Thank You for taking my question and congrats to the management on good set of numbers. Sir,

I have first question on the Jammu plant. Is it possible to give how much was the contribution for this quarter? And any change in guidance for the next year for the revenues coming in from

Jammu plant?

Lokesh Bhasin

During the Quarter 4 FY '25, see, our Jammu plant start commercialized operation from 14th of

January 2025. And for this Quarter 4 '25, Jammu plant contributed a revenue of around INR36 crores. And coming to the next question, so as of now, we maintained our guidance of that

Jammu plant is poised to achieve a revenue of around INR400 crores for this financial year FY

'26.

Amey Chalke

Okay. And second question I have is on the cash flow. This year, our operating cash has increased with more than double-digit but working capital has eroded the cash from operation has gone down year-on-year. So, any reason for the working capital increase or do you expect it to normalize in the next year?

Lokesh Bhasin

Yes, Amey. So, you are right that this year, our working capital has -- working capital investment has slightly increased. So, there are major 2 reasons for it. Number one is the increase in operations and the working capital required to feed that increase in operations was invested. And at the same time, since Jammu has just started, so that initial working capital to start the plant was required. So, we are hopeful that in coming times, this working capital will return back to the normal days.

Amey Chalke; Sure. Thank You and I will join back the queue

Lokesh Bhasin

Thank You Amey

Moderator

The next question is from the line of Vidit Shah from Spark Capital.

Vidit Shah

My first question was on the Jammu plant, because of the tensions going on in the state right now, are you seeing any impact on our operations there currently?

Vinay Lohariwala

So, as you all are aware that there was blackout in entire almost North-western India, including our HO location, say, Chandigarh. So, the tension was there that facility is near border. So, there was some restlessness, but we have the full faith in our Indian army and our government and everything goes in a well manner. And in future also, we have the full faith in our army and the government. And hopefully, nothing wrong will happen.

Page 5 of 14

Innova Captab Limited

May 20, 2025

Vidit Shah

But in the current quarter, we've just seen a couple of days of blackout and no major impact on operations?

Vinay Lohariwala

So, there was no shutdown in our facility for even a single day. So, we work as usually. There was no hurdle to our facility.

Vidit Shah

Okay. Understood. My second one was on the gross margin that we've seen improve both Y-o-

Y and quarter-on-quarter. I think over the last couple of years, this is the highest ever gross margin that we reported. So, can you help us understand what is driving this improvement in gross margins and what could be the sustainable level going forward?

Lokesh Bhasin

So, Vidit, the gross margin improvement is mainly driven by a couple of reasons, which is our operational efficiency, a better product mix, bearing the best optimum resources or optimal use of the resources that we are having. So, these are the soft and the subjective reasons why our gross margins are increasing, coupled with the decent -- the best product mix that we have there.

And in coming times also, we estimate that this is going to maintain in same trajectory.

Vidit Shah

Okay. But when we talk about segmentally, would margins be similar across, let's say, Sharon and the CDMO business in terms of gross margins? Or would there be a big deviation in these?

Lokesh Bhasin

So, Vidit, we normally do not track gross margins and margin profile at our business areas level.

Vidit Shah

Okay. No, I mean, Sharon is a separate entity itself, right? So that's why I was asking whether compared to Innova, how would Sharon's gross margins fare?

Lokesh Bhasin

So yes, you're right. So, if I talk about ICL manufacturing capability and Sharon manufacturing capability, yes, Sharon is having a slightly better gross margin, but they are having a different target market because they are majorly into regulated market in exports. So, yes, they are having slightly better gross margin profile than ICL manufacturing capabilities.

Vidit Shah

Okay. And just the last one on Sharon, in your opening remarks mentioned that it's well positioned for growth and value creation going forward. If you could just shed some light on what are the management's plans with regards to driving growth in Sharon? And what geographies and products are likely to drive growth? That's it from me.

Vinay Lohariwala

Yes. So, in Sharon that we are currently, say, most of the revenue is coming from Europe and

Canada or the other regulated markets like Australia. And we will focus in Sharon in all these markets. We are trying to expand the wallet share from the existing customer and the onboarding of the new customer in the regulated market.

Moderator

The next question is from the line of Avnish from Vaikarya.

Avnish

I just have a couple. One, Lokesh, for you, I was -- if we have to estimate, let's say, the volume growth in Baddi, which is ex Jammu, and you said that Jammu contributed INR36 crores. If I remove INR36 crores from the standalone P&L, both from the top line and from the gross profit, it seems like the Baddi volume growth was around 12% to 13%. Is this calculation, right? Or is there some error in it?

Page 6 of 14

Innova Captab Limited

May 20, 2025

Lokesh Bhasin

So, see, if I talk about at a full year level, ICL growth was ex Jammu was around 7% at a revenue from operation level.

Avnish

No, I was more interested in the quarter for the fourth quarter.

Lokesh Bhasin

Fair enough. So, if I talk about Quarter 4, if I exclude my ICL Jammu revenue part, so the growth was around 4% to 5% from year-on-year basis.

Avnish

Yes. That's the revenue. So, I was looking at -- I mean, if you remove the Jammu contribution, gross profit.

Lokesh Bhasin

So actually, see, I would just like to highlight that, see, we cannot see ICL Baddi operation in isolation. As we briefed earlier in our previous calls also that there is a certain level of cannibalization at initial level wherein, we are moving our revenue from our existing Cepha facility in Baddi to our new upcoming facility in Jammu of Cepha Block.

So, there is a certain element of cannibalization from Baddi to Jammu at an initial period itself.

So that impact is also reflected in our ICL Baddi operation if you see it is standalone. But as I submitted, it cannot be seen in isolation per se.

Avnish

Okay. Understood. If we look at, let's say, when you guide for INR400 crores revenue from

Jammu, that is over and top of the non-Jammu revenues that we've closed on this year, right?

So, your non-Jammu revenues this year were close to about INR1,208 crores. What kind of growth can we expect in this? And then is INR400 crores over and top of that?

Lokesh Bhasin

So, my -- you are right. So out of my INR1,244 crores, my non-Jammu was around INR1,208 crores.

Avnish

Yes.

Lokesh Bhasin

So, the way I look at it, we are maintaining that we should be growing in early teens for our existing facilities. Plus, over and above the revenue that we'll get from Jammu plant.

Avnish

That's right. So, if you assume like about, let's say, early teens for ex Jammu business and the

INR400 crores over and above that. That's how we should understand it.

Lokesh Bhasin

True.

Avnish

Okay. Last question from my side. How was the GST benefit accounted in this quarter? I mean, the benefit is in gross profit or in the other income. Can you please help us understand that?

Lokesh Bhasin

Yes. So, the way we accounted for with the blessings of Statutory Auditors, we have recorded our GST benefit as other operating income as a part of revenue from operations.

Avnish

Thanks. Thanks Lokesh. Thanks Vinayji

Moderator

The next question is from the line of Saket from Sagari Capital.

Page 7 of 14

Innova Captab Limited

May 20, 2025

Saket

Yes. So, sir, my first question is pertaining to the CDMO segment. So, it has shown around 6% of growth. So, can you help me break up this into volume and say, price growth terms?

Lokesh Bhasin

So, my major revenue growth for CDMO business was for manufacturing capabilities business as mainly driven by volume growth.

Saket

And what could be that sir? Because I think we have seen that API prices have been down trending. So, was it like there was price de-growth as well? Or what was the breakup?

Lokesh Bhasin

See, if I talk about a year-on-year basis, other, I would like to emphasize that if I see my growth at a volume level, I would like to see at a manufacturing capability level instead of a business area level. So, on a full year level, we have got a volume growth of around 7% to 8%, and which is now in the growth that we have recorded at our ICL manufacturing capability level.

So whatever price impact was there, so due to product mix and other variable reasons during the year, it has been knocked off. There may be a slightly variation of 1% or 2%, but on a majorly, it is driven by volume growth.

Saket

Okay. Sir, on top of that, your Domestic Branded Generics has also done quite well. Now at

21%, so how do you break that up into, say, typical IPM drivers? Like how much was NI contributing? How much was price growth and how much was volume growth?

Lokesh Bhasin

So even in Domestic Branded Generics, the major growth has driven by our volumes through new products and penetrating into new markets or getting deep into our existing markets.

Saket

Okay. And sir, what would be the guidance for Domestic Branded Generic business, say, for the coming up? Because it would, say, behave slightly differently from the typical manufacturing business, right? So, any different color or growth number that you might have -- want to share on this -- for this segment?

Lokesh Bhasin

So, the way we see it, it should be in the line with the overall company growth itself.

Saket

Okay. So, which is mid-teens that you said, right, 12-13% is that the fair -- non-Jammu that you just mentioned, is it?

Lokesh Bhasin

See, when I see Jammu, see, there are two -- I would just like to explain on that part. See, business area is my front end, which delivers my sales. At the same time, Jammu is a manufacturing capability. So, my manufacturing capability of Baddi as well as Jammu feeds my all three business areas, which is CDMO, Domestic Branded Generics and International Branded

Generics.

So, the way my Baddi manufacturing capability is working to feed all these three front-end business areas, the same way Jammu is also coming up and it will feed my all three business areas, either it's CDMO, Domestic Branded Generics or International Branded Generics.

Saket

Got it. So, sir, for Domestic Branded Generics, you don't source anything from outside because there might be some products where you may not have enough scale. So, is like 100% is in- sourced for both International Branded as well as Domestic Branded?

Page 8 of 14

Innova Captab Limited

May 20, 2025

Lokesh Bhasin

So, talking about Domestic Branded Generics, yes, there is a certain element of items, which normally Innova do not produce that we procure from our third-party outside vendors, but that is not that much. It's hardly 20-25%.

Saket

Okay. Got it. And sir, in terms of, say, just order of, say, profitability, so like is it like Sharon would be the highest and then followed by branded generics and then CDMO would be the least profitable within these 4 segments? Is it a fair, say, order? Or how would that be?

Lokesh Bhasin

As I submitted earlier also, normally, we do not track margins at our business areas level. But if

I talk about at a gross margin of a manufacturing capability, yes, Sharon being in regulated market, they will slightly -- they generate slightly better gross margins.

Saket

Thanks Sir for taking the question and I appreciate it and best of luck

Lokesh Bhasin

Thank You

Moderator

The next question is from the line of Miten Lathia from Fractal Capital Investments.

Miten Lathia

Three questions on Jammu. First, while you recognized the GST benefit as other operating income, could you clarify if it is an amount that is paid and then claimed as refund or it doesn't need to be paid at all, it directly is accounted for as income? Second, our current mix on the

CDMO side is -- I understand that it's around 50-50.

Why have you chosen to increase the mix of acute at the Jammu facility? If you could spend a couple of minutes to thought process around that? And number three, you guided for about

INR400 crores of incremental revenue from Jammu in FY '26. If you could sort of help us understand, how is it that you have that visibility of that revenue?

Lokesh Bhasin

Sir, answering to your question number one, so the way this GST incentive works is that we pay and we take the input credit of GST as per normal business practice, the way it is done for other manufacturing areas. But as we are supported by central government scheme. So whatever GST that we have paid on our total domestic sales at the end of the quarter, we will file a separate refund return to central government to claim that incentive back from central government.

So, these are two process. Number one is the normal GST process will remain same as other business -- other geographical location for a manufacturing business. Added step is that whatever

GST that we have paid on sales invoices of domestic sales, we will file the return -- refund return to central government at a quarter end. I hope this satisfies your question.

Miten Lathia

Yes.

Vinay Lohariwala

So, the second question regarding the selection of product and facility. So, in Baddi, say, we are already into the general facility and cephalosporin facility. And this is extension of our product basket in the category of the other antibiotic like beta-lactam and penem and then general category of LVP, respules is there and then the waterfall injection. So, the strategic decision is taken based on the requirement in the market and our present capability.

Miten Lathia

And the third bit on the visibility around the INR400 crore number.

Page 9 of 14

Innova Captab Limited

May 20, 2025

Vinay Lohariwala

So as on date, we are very much confident that this number is achievable. And being four facility, so say, if we say, like INR400 crores, sometimes it looks quite aggressive. But if we divide in the four plants, so it's not 1 facility, but there are four block.

So, it's like INR100 crores. And each quarter, if we see, then it come out to be, let's say, INR25 crores each block. So, then the number becomes smaller. So, the number has given on the fair assessment and estimation, and that's why we are giving that number, and we are very confident to achieve that.

Mithen Lathia

So Sir, I’ll come back in the queue

Moderator

The next question is from the line of Divesh Tated from Finterest Capital.

Divesh Tated

Yes, sir. So, I guess in the last -- second last quarter, you have guided for INR2,500 crores of revenue in next 3 years. So, are we still on that? Are we confident on that?

Lokesh Bhasin

Yes, Divesh. So, where we seek to over long term, we are very much confident that we should be maintaining the CAGR of 25% revenue growth over the next 3 years.

Divesh Tated

Okay. Okay, sir. And sir, my next question is regarding as and when we utilize our Jammu plant more better, so our margins and even the GST incentive that we have, our margin getting better in next 3 years to, I guess, 17%. Is that right, sir?

Lokesh Bhasin

So while we will not like to comment on the number -- exact number, but yes, by increase of operations, get the benefit of operating leverage, the GST benefit, our operations efficiencies coming due to economies of scale and getting new products, yes, the margin is bound to increase.

Divesh Tated

Ok, Ok. Thank You so much sir. That’s it from my side

Lokesh Bhasin

Thank You

Moderator

The next question is from the line of Vidit Shah from Spark Capital.

Vidit Shah

Just one clarification, sir, this INR400 crore number that you've guided from Jammu, does that include the GST benefit? And if so, how much would that be.

Lokesh Bhasin

Yes. So, when we say the number, yes, normally, as it is a part of our other operating revenue, that GST number is included in our overall INR400 crores as of now.

Vidit Shah

And would you be able to quantify that number, sir?

Lokesh Bhasin

Sir, it should be in the range of INR30 crores to INR35 crores.

Vidit Shah

Okay. Understood. And the INR36 crores of revenue that we did in 4Q, are we -- what level are we breaking even at? Are we breaking even yet in Jammu?

Lokesh Bhasin

Can you please repeat your question? You were not audible. Sorry.

Vidit Shah

What level of operations would you break even at Jammu?

Page 10 of 14

Innova Captab Limited

May 20, 2025

Lokesh Bhasin

Okay. I think we should be EBITDA positive -- EBITDA neutral, sorry, EBITDA neutral by around sale of INR50 crores to INR55 crores.

Vidit Shah

Ok Got it. Thank You

Moderator

The next question is from the line of Harsh from Bandhan AMC.

Harsh

Yes. Just one or two quick clarifications. Can you help us understand the API pricing scenario as of now? I think so there was some question as well earlier, most of the CDMO growth is volume pertain to volumes. But just from a fourth quarter perspective, if you could help us understand at a broader scale and as things stand today, from an API pricing perspective, how things are and anything specifically from a cephalosporin perspective?

Lokesh Bhasin

Hii Harsh, so if I talk about quarter 4 and as of now status, at a broad level, at a weighted average level, I think more or less, the prices are more or less at a flat level. So, there will be some prices up and down. But if I see from a company's perspective, they are not having just as much impact as of now at the current level.

Harsh

Sure. And anything incrementally from cephalosporin or --?

Lokesh Bhasin

Sorry, I didn't get your question.

Harsh

Pricing in terms of the cephalosporins well, they are also broadly consistent on a quarter-on- quarter basis or anything incremental?

Vinay Lohariwala

So, in cephalosporin, there is slight -- the prices are slightly lower as well as in the beta-lactam.

But overall if we see this -- one thing is that it is difficult to measure. And overall, we see that there are a few areas where the price has been increased and there are a few areas where the price has decreased.

Harsh

Sure. And lastly, from an FY '25 perspective, CDMO is somewhere around 6% to 7% growth rate. So, what would be the volume number on a broader basis for this entire year? I mean, I understand, there will be introductions and pricing. But just that volume number, would it be a double-digit volume number, early teens, mid-teens volume number?

Lokesh Bhasin

You're talking about volume growth? Harsh, are you talking about volume growth?

Harsh

Yes, sir. Volume growth for FY '25 for the CDMO business. Overall reported number is 6% to

7% growth for FY '25. What would be the volume growth number? Would it be like close to high single digits or low double digits?

Vinay Lohariwala

It's slightly better than the reported number growth. So that's why we are saying that even for the full year, the price impact is flat. So, it's just not only the function of the price growth once we capture the volume versus average price. So, then the product mix change is also a factor.

Harsh

Okay. So broadly, we should work with a similar number for the volume growth as well as compared to the reported number?

Page 11 of 14

Innova Captab Limited

May 20, 2025

Vinay Lohariwala

Yes, yes. So -- better than the price -- better than the value growth, but volume growth is like 1 or 2 percentage points better.

Moderator

The next question is from the line of Amey Chalke from JM Financial.

Amey Chalke

Yes. I just had one question on the upcoming R&D facility in Panchkula, Haryana, which says that we would like to develop generic and complex generic products and some of the products are like immediate release, super bioavailability capsules, nano size formulations, etc. So, what are the markets are we going to target with these products?

Vinay Lohariwala

Amey, as you know that at Sharon, we are working in the regulated market space. And the thing was that in Sharon, as we don't have any independent R&D setup. So, where the Innova is helping, we are taking the regulated market project and developing at the Innova R&D and then we are doing the exhibit bets at Sharon to file in the regulated market. So one is that.

The other one is that even we are open for the domestic market and the ROW market. So overall, the product -- once the product is developed, it can be filed in the various market as per the requirement.

Amey Chalke

Right. So, these will be our own IP products even for regulated markets, you mean to say?

Vinay Lohariwala

Yes, yes. So, in regulated market, there are the 2 types of business. One is the tech transfer. The other one is this one, where we have our own IP and on developed dossier and then we have the commercialization.

Amey Chalke

But the commercialization will happen through partners, you mean to say that we won't be doing it on our own.

Vinay Lohariwala

Yes, yes. So, we have the -- we choose or we collaborate with the partner and the filing is being done. After that, once the required approvals is received, then we can do the commercialization.

So, after acquiring the Sharon, we have done like a few of the products from the Sharon to the regulated market on this theme only.

Amey Chalke

And is there supposed to be any impact on overall company margins on increased spend on this

R&D facility?

Vinay Lohariwala

So, let's say, it helps in the incremental business. But being, say, at INR1,200 crores in future, let's say, if we reach towards INR2,500 crores, then these businesses like INR50 crores, INR100 crores will have a less impact on the overall margin.

Amey Chalke

Got it. So, you don't expect immediate impact. Maybe once the scale is there on the top line, then the impact would be negligible what you meant?

Vinay Lohariwala

Yes, yes, yes. So overall, our strategy is to efficiently, effectively use our manufacturing facility with a more value-added product in a regulated and semi-regulated market. So, our R&D facility will help in achieving that.

Amey Chalke

Thank You so much. I will join back

Page 12 of 14

Innova Captab Limited

May 20, 2025

Vinay Lohariwala

Thank You

Moderator

The next question is from the line of Miten Lathia from Fractal Capital Investments.

Miten Lathia

Just one question on Sharon. While you said that, in regulated markets, you want to broaden the customer base, but we've had almost 4 years of flat revenues at Sharon. So, is the current product portfolio something that can drive a 3-year sort of growth outlook? Or if you can sort of spell out what you are thinking about that business over the next 3 years or so?

Vinay Lohariwala

Yes. So, as you are aware that Sharon being in CIRP, there were no new initiation, new steps has been taken. Once we integrate -- and I think June -- to 1.5 year back, then we start taking new projects and all that. So that will mature in the coming quarters and coming year as there is a long lead time for -- long gestation time for in a regulated market. So, we see that all positivity should reflect in this upcoming year.

Miten Lathia

Okay. Just to be clear, you are saying that in the two existing markets of Europe and Canada, you want to deepen the relationship with the existing customers by offering them more products.

Is that what you had mentioned earlier or --?

Vinay Lohariwala

Yes. So, onboarding of the new customer as well as onboarding of new products with the existing customer. Or let's say, what we used to do 4 years, 5 years back, revival of that business is also the part of strategy in Sharon.

Miten Lathia

So, they have actually lost products within customers or they've lost customers altogether in the last 4 years. Is that…

Vinay Lohariwala

So, let's put it in this way, the company being in CIRP, there was some hurdle in acquiring the new business and all that. So once the Innova name is there, the customer is also having a good confidence and all supply side hurdle has been removed, right?

So, we are focusing on that business and doing our all efforts to revive and grow at a positive growth rate. And as you are saying that that is absolutely correct that revenue is almost flat. But if you see the EBITDA and profit margin, that has been consolidated in a very good manner.

Mithen Lathia

Understood sir. Thank You

Moderator

The next question is from the line of Divesh Tated from Finterest Capital.

Divesh Tated

I just had one last question. Sir, I wanted to know what could be the run rate for depreciation going forward.

Lokesh Bhasin

So over and above existing depreciation rate, the Jammu plant would be having a depreciation of around INR24 crores to INR25 crores per annum.

Divesh Tated

Okay. Okay. And our existing business will not have any such or they will have depreciation?

Lokesh Bhasin

They would continue the existing depreciation rate. There may be certain maintenance capex, but the depreciation rate would be in the same lines that they are having right now.

Page 13 of 14

Innova Captab Limited

May 20, 2025

Moderator

Thank you so much. As there are no further questions from the participants, I now hand the conference over to management for closing comments.

Vinay Lohariwala

Thank you, everyone, for joining us for the earnings call. We appreciate your time and showing interest. In case of any queries, you can get in touch with our Investor Relations team. We look forward to meeting all of you over the next call. Thank you very much again.

Lokesh Bhasin

Thank you.

Moderator

On behalf of Innova Captab Limited, that concludes this conference. Thank you for joining us and you may now disconnect your lines.

Page 14 of 14